Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio (Nasdaq: VOR), a clinical-stage biotech company, has granted significant equity incentives to its new Chief Development Officer, Dr. Qing Zuraw.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vor Bio (Nasdaq: VOR), a clinical-stage biotech company, has granted significant equity incentives to its new Chief Development Officer, Dr. Qing Zuraw. The compensation package includes 4,373,040 stock options at an exercise price of $2.38 per share and 937,080 restricted stock units (RSUs).
The grants, effective July 17, 2025, were made under the Vor Biopharma Inc. 2023 Inducement Plan as a material inducement to employment, complying with Nasdaq Listing Rule 5635(c)(4). The stock options have a 10-year term with a four-year vesting schedule, while RSUs will vest quarterly over four years, starting August 1, 2026.
Details
News Market Reaction – VOR
The recorded move for VOR in the trading session of this news was -7.24%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective as of July 17, 2025, the Compensation Committee of the Board of Directors granted Qing Zuraw, M.D., the Company’s Chief Development Officer, 4,373,040 stock options and 937,080 restricted stock units (“RSUs”) in connection with the commencement of her employment. The foregoing stock option and RSU awards were granted as a material inducement to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
The stock options have a ten-year term and an exercise price of
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com
Investor Contacts:
Sarah Spencer
+1 857-242-6076
investors@vorbio.com
Carl Mauch
investors@vorbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.